Industry Overview - Genomics is a comprehensive study of genomes, which has gained significant interest from pharmaceutical and biotechnology companies for understanding diseases and developing therapies [2] - The distinction between genetics and genomics is crucial, with genomics focusing on the complete set of genes and their interactions within an organism [3] - Insights from genomic research are increasingly utilized to evaluate patient responses to drugs and support the development of targeted therapies, advancing personalized medicine [4] - The growth of genomics has also bolstered synthetic biology, which applies engineering principles to biology for various applications, including drug discovery and gene editing [5] - The rapid advancements in genomics are driven by significant reductions in the cost and time required for genome sequencing [6] Market Projections - The genomics market is projected to reach $80.17 billion by 2032 [9] - The global synthetic biology market was valued at $18.94 billion in 2025 and is expected to grow at a CAGR of 17.7% from 2026 to 2033 [9] Key Companies - **Pacific Biosciences of California (PACB)**: Specializes in advanced long-read sequencing systems for various applications, including healthcare and agriculture. The company has a Zacks Rank 2 (Buy) [12][14] - **Wave Life Sciences (WVE)**: A clinical-stage biotechnology company focusing on RNA medicines. The company reported positive interim data for its obesity treatment candidate WVE-007, which showed improvements in body composition [15][17] - **Sana Biotechnology (SANA)**: Developing cell engineering platforms for diseases like type 1 diabetes and B-cell cancers. The company has suspended its CAR T programs to focus on more promising candidates and has a Zacks Rank 3 [19][21]

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Twist Biosciences Corporation is one of the most promising stocks on our list. TheFly reported on December 15 that Barclays raised its price target for TWST from $37 to $39 while maintaining an Overweight rating, reflecting confidence in the company’s margin progress and anticipated performance in the life sciences tools sector. This follows an Overweight initiation on November 3, 2025, by Stephens with a $41 p ...

"Our dual-function approach is designed to provide an unprecedented level of precision, effectively illuminating hidden tumors from within the body, which then signals the presence of disease through a simple urine test," explained Taylor. "This is a scientific leap forward that we believe will profoundly change how we approach early cancer diagnostics." "We are truly excited to get to support this effort," said Jesse Dill, Government BD Lead at Ginkgo Bioworks. "This type of interdisciplinary teaming, and ...

Industry Trends & Competitive Landscape - Biotech industry experienced a boom, but America's lead is slipping as China prioritizes synthetic biology [1] - Urgent need for strong American presence and young American leaders in the next generation of biotechnology [2] Scientific Advancements & Potential Breakthroughs - Lambert's project has the potential to be a major scientific breakthrough if further testing is successful [3] - A better diagnostic for Lyme disease has been developed, applicable beyond Lyme disease [3] Technology & Delivery Methods - Lipid nanoparticles are being considered as a delivery method [2]

Hopes were high as the Eiffel Tower when the students from Atlanta landed in Paris at the end of October. More than 400 teams, a third of them high schoolers, were competing in IGM 2025. Elite synthetic biology with a dash of nerdp proud culture.>> My first time coming here, I was so overwhelmed. >> This was Oan Carik's third year at Jim and she was keeping an eye on the other teams. Is there a project here that has blown your mind.>> Almost every single one. >> One was just a few feet away from their booth ...

How do you think you're going to do. >> I'm hoping we finish top 10, but even that I don't know. We'll see.>> That would be top 10 out of 140 teams. >> Fingers crossed on wood. >> Knock on wood.Everything. >> We're here to celebrate each and every one of you for all of your hard work, creativity, and enthusiasm. >> On IGM's final day, it was time to see what a year of work had earned Lambert High School.The nominees are >> It was a nailbiter. >> They were nominated in five different categories and kept gett ...

Are you thinking to yourself, this needs to be in every school. >> Yes. Oh, that's been our goal since day one is let's start with Georgia as a little test bid and see what we can do here.>> She left Lambert three years ago after securing federal funding to take synthetic biology to high schools all across Georgia. But the Trump administration cut the money, claiming it fell under DEI, diversity, equity, and inclusion. A judge temporarily restored the funding, but StandeDev told us she's not sure it will ex ...

In Lambert High School's lab, Shaun Lee and his classmates are teenage genetic engineers manipulating the building blocks of life. >> And what we're going to do is we're going to move each of these samples into these mixes. And these mixes have everything we need in order to amplify our DNA.>> It's It's currently amplifying. >> Yes. All right.And we'll have to do this three more times for our different samples. So you would kind of swipe across. >> We went to check out the IGM team's project for the big Par ...

Industry Overview - Genomics is a comprehensive study of genomes, focusing on the complete set of DNA in an organism, and is gaining interest from pharmaceutical and biotechnology companies due to recent breakthroughs [1] - The distinction between genetics and genomics is important; genetics focuses on individual genes, while genomics aims to characterize all genes and their interactions within a living system [2] - Insights from genomics are increasingly used to develop targeted treatments and advance personalized medicine, addressing the rising demand for innovative medical therapies [3] Technological Advancements - The field of genomics has led to the emergence of synthetic biology, which applies engineering principles to biology for applications such as drug discovery and gene editing [4] - Significant progress in genomics has been driven by reductions in the cost, time, and effort required for genome sequencing, with Illumina being a major player in this space [5] - Genome-editing technologies, particularly CRISPR/Cas9, are being explored by companies like CRISPR Therapeutics AG and Intellia Therapeutics to treat diseases caused by genetic mutations [7] Market Projections - The genomics market is projected to reach $80.17 billion by 2032, while the synthetic biology market was valued at $16.2 billion in 2024 and is expected to grow at a CAGR of 17.30% from 2025 to 2030 [8] Investment Opportunities - Companies such as Editas Medicine, Sana Biotechnology, and Pacific Biosciences of California are highlighted as potential investment opportunities in the genomics and synthetic biology sectors [9] - Editas Medicine is developing EDIT-401, a gene editing therapy aimed at reducing LDL-cholesterol, showing over 90% reduction in preclinical tests [10][11] - Sana Biotechnology is focusing on cell engineering platforms for diseases like type 1 diabetes and B-cell cancers, with plans for IND applications in 2026 and 2027 [15][16][17] - Pacific Biosciences of California specializes in advanced sequencing solutions, with a focus on HiFi long-read sequencing technology, and has seen a 53.9% increase in shares over the past six months [18][19]

Core Insights - Artisan Partners' "Artisan Small Cap Fund" reported strong performance in Q3 2025, with major US indices reaching record highs and the fund's Investor Class returning 8.69% [1] - Twist Bioscience Corporation (NASDAQ:TWST) was highlighted as a detractor in the fund's performance, with a one-month return of -20.34% and a 52-week loss of 37.05% [2][3] Fund Performance - The Artisan Small Cap Fund's Advisor Class fund returned 8.75%, and the Institutional Class fund returned 8.73%, while the Russell 2000 Growth Index returned 12.19% [1] - The fund's top 5 holdings were mentioned as key picks for 2025 [1] Company Analysis: Twist Bioscience Corporation - Twist Bioscience reported 18% revenue growth, driven by demand in next-generation sequencing, despite weaker sales in synthetic biology products [3] - The company has a market capitalization of $1.58 billion, with shares closing at $26.87 on November 14, 2025 [2] - The partnership with Veracyte is viewed as a validation of Twist's platform, potentially driving long-term upside [3] Hedge Fund Interest - Twist Bioscience was held by 23 hedge fund portfolios at the end of Q2 2025, a decrease from 30 in the previous quarter [4] - The company reported revenue of $99 million in Q4 2025, reflecting a 17% year-over-year growth [4]